Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.26
- Piotroski Score 2.00
- Grade Neutral
- Symbol (SIOX)
- Company Sio Gene Therapies Inc.
- Price $0.42
- Changes Percentage (0%)
- Change $0.42
- Day Low $0.42
- Day High $0.42
- Year High $0.42
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 02/08/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 02/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.39
- Trailing P/E Ratio -1.225641025641
- Forward P/E Ratio -1.225641025641
- P/E Growth -1.225641025641
- Net Income $-71,887,000
